| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Galectin-3
Galectin-3 (Gal-3), a carbohydrate-binding protein (lectin) involved in cell adhesion, migration, activation, and apoptosis. Gal-3 is implicated in cancer progression, fibrosis, inflammation, and heart failure. |
|---|---|
| ln Vitro |
In vitro, Galectin-3 antagonist 1 (compound 15) is a potent and selective Galectin-3 antagonist with a Kd value of 5.3 uM. It shows selectivity over other galectins, with Kd values of 250 uM (Gal-4N), 18 uM (Gal-4C), and 450 uM (Gal-8C). This suggests it can be used to probe Gal-3-specific functions in cellular assays.
|
| ln Vivo |
No published in vivo data. As a selective Gal-3 antagonist, it would be expected to reduce Gal-3-mediated effects in vivo, such as reducing fibrosis in liver or lung injury models, inhibiting tumor growth, or attenuating cardiac remodeling in heart failure models, though this remains to be validated.
|
| Enzyme Assay |
A direct binding fluorescence polarization (FP) or SPR assay is used: recombinant human Gal-3 protein is incubated with a fluorescently labeled lactose probe in the presence of serially diluted antagonist 1 (0.1-1000 uM). The Kd is calculated from the competition curve. Selectivity is determined by testing binding to other galectins.
|
| Cell Assay |
For in vitro cellular assays, epithelial or cancer cell lines expressing high levels of Gal-3 are treated with serial dilutions of Gal-3 antagonist 1 (1-100 uM) for 24-72 hours. Gal-3-mediated functions such as cell aggregation, migration (wound healing assay), or apoptosis resistance are assessed. Inhibition of Gal-3 binding to cell surface glycoconjugates can be detected by flow cytometry using a labeled Gal-3 probe.
|
| Animal Protocol |
No published in vivo data. For research use, a mouse model of pulmonary fibrosis (bleomycin-induced) or liver fibrosis (CCL4-induced) can be used. Mice are treated with Gal-3 antagonist 1 (5-30 mg/kg, i.p. or oral) daily for 2-4 weeks. Lung/liver tissues are harvested for histopathological analysis (Masson‘s trichrome staining) and hydroxyproline content measurement.
|
| ADME/Pharmacokinetics |
Gal-3 antagonist 1 has a molecular weight of 495.86 g/mol and a formula of C22H22ClNO10. DMSO solubility is 100 mg/mL (201.67 mM). Detailed PK parameters are not publicly available; as a small molecule, PK properties will depend on formulation and administration route, with oral bioavailability likely moderate.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles are not publicly available. As a small molecule antagonist of Gal-3, no severe toxicities are expected at efficacious doses based on the absence of major safety concerns with other Gal-3 inhibitors. General toxicity studies have not been reported.
|
| References | |
| Additional Infomation |
Gal-3 antagonist 1 is a research chemical not approved for clinical use. It is a reference compound used to study Galectin-3 biology, selectivity profiling of galectin inhibitors, and to evaluate Gal-3 as a therapeutic target in inflammation, fibrosis, and cancer. It is extracted from patent literature and available for laboratory research.
|
| Molecular Formula |
C22H22CLNO10
|
|---|---|
| Molecular Weight |
495.863786220551
|
| Exact Mass |
495.093
|
| CAS # |
2921603-03-2
|
| PubChem CID |
164513432
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
34
|
| Complexity |
725
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC1=CC=C(C=C1)C(=O)O[C@H]2[C@H]([C@H](O[C@H]([C@H]2OC(=O)C3=C(C=C(C=C3)Cl)[N+](=O)[O-])OC)CO)O
|
| InChi Key |
FSBFERQGFVBNEJ-NOYKIMNZSA-N
|
| InChi Code |
InChI=1S/C22H22ClNO10/c1-11-3-5-12(6-4-11)20(27)33-18-17(26)16(10-25)32-22(31-2)19(18)34-21(28)14-8-7-13(23)9-15(14)24(29)30/h3-9,16-19,22,25-26H,10H2,1-2H3/t16-,17+,18+,19+,22-/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-methoxy-4-(4-methylbenzoyl)oxyoxan-3-yl] 4-chloro-2-nitrobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (201.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0167 mL | 10.0835 mL | 20.1670 mL | |
| 5 mM | 0.4033 mL | 2.0167 mL | 4.0334 mL | |
| 10 mM | 0.2017 mL | 1.0083 mL | 2.0167 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
